Fred Fiedorek - Articles and news items


XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes

Industry news / 22 January 2014 / AstraZeneca

AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union…

Bristol Myers Squibb logo

U.S. FDA grants priority review for Metreleptin

Industry news, News / 4 June 2013 / Bristol-Myers Squibb Company

Metreleptin, an investigational agent for treatment of metabolic disorders associated with rare forms of LD…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...